Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. SEC filings document the company’s operating results, material events and governance as a NYSE-listed construction services issuer. Recent 8-K filings report quarterly and fiscal financial results, cash dividends, share repurchase program actions, and engineering, procurement and construction contract developments involving Gemma Power Systems and power-generation projects.
Proxy materials cover board elections, executive compensation, equity awards, shareholder voting matters and related governance disclosures. The filings also identify Argan’s common stock registration and formal event reporting for capital allocation and project-backlog developments.
Charles E. Collins IV, Chief Executive Officer of Argan, Inc. (AGX), reported option exercise and open-market sale on September 24, 2025. He exercised 5,000 shares from an option granted September 12, 2019, at an exercise price of $43.10 per share, and immediately sold 5,000 common shares on the open market at $267 per share. Following these transactions the Form 4 reports 26,006 shares beneficially owned after the exercise and 21,006 shares after the sale; the filing also records ownership of options underlying 5,000 shares and total derivative beneficial ownership of 39,735.
The Form 4 is signed and dated September 26, 2025, and identifies Collins as an officer (CEO). The filing documents standard Section 16 reporting of insider option exercise and subsequent disposition of shares.
Peter W. Getsinger, a director of Argan, Inc. (AGX), sold 1,000 shares of the company's common stock on September 19, 2025, on the open market at an average price of $264.54 per share. After the sale, Getsinger beneficially owned 11,896 shares directly. The Form 4 was signed on September 23, 2025, and lists Getsinger's Edgartown, MA address and director status. No derivative transactions or amendments are reported and the filing indicates this was a routine open-market disposition executed at the stated price.
Peter W. Getsinger, a director of Argan, Inc. (AGX), sold 1,000 shares of the company's common stock on September 19, 2025, on the open market at an average price of $264.54 per share. After the sale, Getsinger beneficially owned 11,896 shares directly. The Form 4 was signed on September 23, 2025, and lists Getsinger's Edgartown, MA address and director status. No derivative transactions or amendments are reported and the filing indicates this was a routine open-market disposition executed at the stated price.
Karen A. Sweeney, a director of ARGAN INC (AGX), reported a sale of company stock on September 19, 2025. She sold 390 shares of the issuer's common stock on the open market at a price of $264.25 per share and after the transaction beneficially owned 1,315 shares directly. The Form 4 was signed by the reporting person on September 22, 2025. The filing records the transaction type as an open-market sale and specifies direct ownership following the sale.
Karen A. Sweeney, a director of ARGAN INC (AGX), reported a sale of company stock on September 19, 2025. She sold 390 shares of the issuer's common stock on the open market at a price of $264.25 per share and after the transaction beneficially owned 1,315 shares directly. The Form 4 was signed by the reporting person on September 22, 2025. The filing records the transaction type as an open-market sale and specifies direct ownership following the sale.
James W. Quinn, a director of Argan Inc. (AGX), disclosed open-market sales of the issuer's common stock on September 19 and September 22, 2025. He sold 11,897 shares on September 19 at an average price of $260.73 per share, leaving 4,660 shares held directly after that transaction. He then sold the remaining 4,660 shares on September 22 at an average price of $259.35 per share, leaving no direct holdings. The filing also shows indirect ownership of 63,014 shares through the James W. Quinn 2025 GRAT No.1. The transactions are reported on a Form 4 and were signed by Mr. Quinn on September 22, 2025.
James W. Quinn, a director of Argan Inc. (AGX), disclosed open-market sales of the issuer's common stock on September 19 and September 22, 2025. He sold 11,897 shares on September 19 at an average price of $260.73 per share, leaving 4,660 shares held directly after that transaction. He then sold the remaining 4,660 shares on September 22 at an average price of $259.35 per share, leaving no direct holdings. The filing also shows indirect ownership of 63,014 shares through the James W. Quinn 2025 GRAT No.1. The transactions are reported on a Form 4 and were signed by Mr. Quinn on September 22, 2025.
Charles E. Collins IV, CEO of Argan, Inc. (AGX), reported option exercise and subsequent open-market sale on 09/18/2025. He exercised 7,500 shares of a stock option granted 09/12/2018 at an exercise price of $43.10 per share, and immediately sold 7,500 shares on the open market at $257.39 per share. Following these transactions the filing shows 21,006 shares beneficially owned directly and 44,735 shares underlying options/derivatives reported as beneficially owned. The Form 4 is signed and dated 09/22/2025.
Charles E. Collins IV, CEO of Argan, Inc. (AGX), reported option exercise and subsequent open-market sale on 09/18/2025. He exercised 7,500 shares of a stock option granted 09/12/2018 at an exercise price of $43.10 per share, and immediately sold 7,500 shares on the open market at $257.39 per share. Following these transactions the filing shows 21,006 shares beneficially owned directly and 44,735 shares underlying options/derivatives reported as beneficially owned. The Form 4 is signed and dated 09/22/2025.
Form 144 Notice — ARGAN INC (AGX): This filing notifies a proposed sale of 1,000 common shares through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $264,535.10 and an approximate sale date of 09/19/2025. The shares were acquired on 04/17/2020 via previously exercised options and paid in cash. The filer discloses two recent sales by the same person in the past three months: 2,609 shares sold on 09/17/2025 for $625,325.12 and 3,465 shares sold on 06/26/2025 for $734,630.59. The filer attests there is no undisclosed material adverse information.
Form 144 Notice — ARGAN INC (AGX): This filing notifies a proposed sale of 1,000 common shares through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $264,535.10 and an approximate sale date of 09/19/2025. The shares were acquired on 04/17/2020 via previously exercised options and paid in cash. The filer discloses two recent sales by the same person in the past three months: 2,609 shares sold on 09/17/2025 for $625,325.12 and 3,465 shares sold on 06/26/2025 for $734,630.59. The filer attests there is no undisclosed material adverse information.
Form 144 notice for Argan, Inc. (AGX) shows a proposed sale of 16,557 shares of common stock through Allen & Company on 09/19/2025, with an aggregate market value of $4,297,866.06. The filing lists 13,811,575 shares outstanding. The shares to be sold were acquired recently: 56,167 shares on 06/09/2025 via an equity grant (paid via option exercise) and 390 shares on 06/10/2025 as a time-based restricted stock issuance. The filer reports no securities sold in the past three months and includes the standard representation that no undisclosed material adverse information is known.
Form 144 notice for Argan, Inc. (AGX) shows a proposed sale of 16,557 shares of common stock through Allen & Company on 09/19/2025, with an aggregate market value of $4,297,866.06. The filing lists 13,811,575 shares outstanding. The shares to be sold were acquired recently: 56,167 shares on 06/09/2025 via an equity grant (paid via option exercise) and 390 shares on 06/10/2025 as a time-based restricted stock issuance. The filer reports no securities sold in the past three months and includes the standard representation that no undisclosed material adverse information is known.
ARGAN, Inc. (AGX) submitted a Form 144 notifying the SEC of a proposed sale of 390 shares of common stock through Raymond James & Associates on 09/19/2025 with an aggregate market value of $103,014.60. The filing reports 13,811,575 shares outstanding for the issuer.
The 390 shares were acquired on 06/10/2025 as a time-based restricted stock issuance from the issuer and were paid on that same date. The filer reports no securities sold in the past three months and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
ARGAN, Inc. (AGX) submitted a Form 144 notifying the SEC of a proposed sale of 390 shares of common stock through Raymond James & Associates on 09/19/2025 with an aggregate market value of $103,014.60. The filing reports 13,811,575 shares outstanding for the issuer.
The 390 shares were acquired on 06/10/2025 as a time-based restricted stock issuance from the issuer and were paid on that same date. The filer reports no securities sold in the past three months and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
ARGAN, Inc. (AGX) Rule 144 notice: The filer plans to sell 49,401 shares of common stock through Raymond James on the NYSE with an aggregate market value of $11,955,042, based on the filing. The shares reported for sale were acquired on 09/18/2025 as an equity grant from the issuer and the payment/transfer is listed as an option exercise on the same date. The filing also discloses two sales by the same person within the prior three months: 1,500 shares sold on 07/29/2025 for $362,250 and 5,000 shares sold on 07/31/2025 for $1,225,000. The filer represents no undisclosed material adverse information.
ARGAN, Inc. (AGX) Rule 144 notice: The filer plans to sell 49,401 shares of common stock through Raymond James on the NYSE with an aggregate market value of $11,955,042, based on the filing. The shares reported for sale were acquired on 09/18/2025 as an equity grant from the issuer and the payment/transfer is listed as an option exercise on the same date. The filing also discloses two sales by the same person within the prior three months: 1,500 shares sold on 07/29/2025 for $362,250 and 5,000 shares sold on 07/31/2025 for $1,225,000. The filer represents no undisclosed material adverse information.
Peter W. Getsinger, a director of Argan Inc. (AGX), exercised stock options and sold a portion of the resulting shares in mid-September 2025. On 09/15/2025 he exercised the remaining 3,000 shares under an option granted 01/07/2016 at an exercise price of $30.44 per share using net settlement, resulting in a reported beneficial ownership of 15,505 shares. On 09/17/2025 he sold 2,609 shares on the open market at $239.68 per share, after which his reported beneficial ownership in common stock was 12,896 shares. The filing shows 3,000 option shares exercised and a remaining derivative position reported as 28,500 option-related shares.
Peter W. Getsinger, a director of Argan Inc. (AGX), exercised stock options and sold a portion of the resulting shares in mid-September 2025. On 09/15/2025 he exercised the remaining 3,000 shares under an option granted 01/07/2016 at an exercise price of $30.44 per share using net settlement, resulting in a reported beneficial ownership of 15,505 shares. On 09/17/2025 he sold 2,609 shares on the open market at $239.68 per share, after which his reported beneficial ownership in common stock was 12,896 shares. The filing shows 3,000 option shares exercised and a remaining derivative position reported as 28,500 option-related shares.